# SLFN12

## Overview
SLFN12 is a gene that encodes the protein schlafen family member 12, which is part of the Schlafen family of proteins known for their roles in cellular differentiation and immune responses. The SLFN12 protein is characterized by its structural domains, including an N-terminal domain and a C-terminal domain, which facilitate its interactions with other proteins and nucleic acids. Notably, SLFN12 forms a complex with phosphodiesterase 3A (PDE3A), which is crucial for its RNase activity and apoptosis-inducing functions in cancer cells (Chen2021Structure; Garvie2021Structure). The protein is predominantly cytosolic and plays a significant role in the differentiation of human enterocytes, influencing the expression of key enzymes involved in carbohydrate digestion (Basson2018Schlafen). SLFN12's interactions and functions suggest its involvement in various physiological and pathological processes, including cancer and multiple sclerosis, highlighting its potential as a therapeutic target (Rhead2018Increased; Singhal2023Schlafen).

## Structure
SLFN12 is a protein characterized by distinct structural domains, including an N-terminal domain (NTD) and a C-terminal domain (CTD). The NTD is further divided into an N-lobe, C-lobe, and two bridging domains, forming a U-shaped valley with positively charged paths that facilitate RNA binding (Garvie2021Structure; Chen2021Complex). The CTD of SLFN12 is involved in forming a complex with phosphodiesterase 3A (PDE3A), primarily through a C-terminal helix that interacts with the catalytic site of PDE3A (Chen2021Structure; Garvie2021Structure).

SLFN12's structure includes a zinc finger motif, which may assist in nucleotide recognition or protein folding (Jo2022Structural). The protein's M-domain acts as a linker and protein-interacting domain, containing a conserved SWAVDL sequence and binding PDE3A (Jo2022Structural). The interaction with PDE3A is crucial for SLFN12's RNase activity, which is hypothesized to be involved in cancer cell cytotoxicity (Garvie2021Structure).

The SLFN12 protein forms a heterotetrameric complex with PDE3A, stabilized by small molecules like DNMDP, which act as molecular glues (Chen2021Structure). This complex formation is essential for the apoptosis-inducing activity of SLFN12 in tumor cells (Chen2021Structure).

## Function
The SLFN12 gene encodes a protein that plays a significant role in the differentiation of human enterocytes, which are cells lining the intestinal tract. SLFN12 interacts with Serpin B12 and deubiquitylases, such as USP14 and UCHL5, to modulate the expression of sucrase-isomaltase, a key enzyme in carbohydrate digestion and a marker of enterocyte differentiation (Basson2018Schlafen). This interaction is crucial for the induction of sucrase-isomaltase promoter activity, and mutations in SLFN12 can reduce its binding ability to Serpin B12, subsequently decreasing sucrase-isomaltase expression (Basson2018Schlafen).

SLFN12 is also involved in mediating the effects of butyrate and mechanical deformation on intestinal epithelial differentiation. It enhances sucrase-isomaltase expression in response to these stimuli, indicating its role in cellular response to environmental changes (Chaturvedi2019Schlafen). The protein is predominantly cytosolic, suggesting it operates through a cytosolic mechanism to influence enterocyte differentiation (Basson2018Schlafen). SLFN12's activity in maintaining enterocyte differentiation highlights its importance in normal physiological processes within the intestinal epithelium (Basson2018Schlafen).

## Clinical Significance
SLFN12 has been implicated in several diseases due to alterations in its expression levels and interactions. In multiple sclerosis (MS), SLFN12 is hypermethylated in CD4+ and CD8+ T cells, leading to reduced gene expression. This hypermethylation is consistent across different datasets and is independent of treatment status, suggesting a potential role in MS pathogenesis (Rhead2018Increased).

In cancer, SLFN12 expression is associated with less aggressive phenotypes. In triple-negative breast cancer (TNBC), SLFN12 reduces cell proliferation and invasiveness, promotes differentiation, and enhances sensitivity to chemotherapy and radiotherapy (Singhal2023Schlafen; RAAFAT2022SLFN12). In lung adenocarcinoma (LUAD), SLFN12 decreases c-myc protein translation, reducing cell proliferation and improving survival outcomes, while its effects are not observed in lung squamous cell carcinoma (AlMarsoummi2020Schlafen).

SLFN12 also plays a role in enterocyte differentiation, where its expression is reduced during prolonged fasting, affecting differentiation markers. This suggests its involvement in conditions like mucosal adaptation and small bowel adenocarcinoma (Basson2018Schlafen). These findings highlight SLFN12's potential as a therapeutic target and biomarker in various diseases.

## Interactions
SLFN12 interacts with several proteins and nucleic acids, playing a significant role in cellular processes. It binds to Serpin B12 and modulates the deubiquitylases USP14 and UCHL5, inhibiting the proteasomal degradation of differentiation transcription factors such as cdx2 (AlMarsoummi2021Schlafens:). SLFN12 also interacts with Phosphodiesterase 3A (PDE3A), forming a complex that is crucial for inducing apoptosis in cancer cells. This interaction is stabilized by small molecules like DNMDP, which promote the formation of a heterotetrameric complex between PDE3A and SLFN12, enhancing SLFN12's RNase activity (Chen2021Structure; Garvie2021Structure).

SLFN12's interaction with PDE3A is mediated by its M-domain, which includes a conserved SWAVDL sequence. This domain also interacts with ribosomal proteins, inhibiting the translation of certain antiapoptotic proteins (Jo2022Structural). The interaction between SLFN12 and PDE3A is further characterized by hydrophobic interactions and hydrogen bonds, with specific residues in both proteins playing key roles in complex formation (Chen2021Structure). These interactions suggest that SLFN12 may serve as a docking site for nucleic acids or functional cofactors, influencing ribosome interactions and translation processes (Jo2022Structural).


## References


[1. (Jo2022Structural) Ukhyun Jo and Yves Pommier. Structural, molecular, and functional insights into schlafen proteins. Experimental &amp; Molecular Medicine, 54(6):730–738, June 2022. URL: http://dx.doi.org/10.1038/s12276-022-00794-0, doi:10.1038/s12276-022-00794-0. This article has 30 citations.](https://doi.org/10.1038/s12276-022-00794-0)

[2. (Chaturvedi2019Schlafen) Lakshmi S. Chaturvedi, Qinggang Wang, Shyam K. More, Emilie E. Vomhof-DeKrey, and Marc D. Basson. Schlafen 12 mediates the effects of butyrate and repetitive mechanical deformation on intestinal epithelial differentiation in human caco-2 intestinal epithelial cells. Human Cell, 32(3):240–250, March 2019. URL: http://dx.doi.org/10.1007/s13577-019-00247-3, doi:10.1007/s13577-019-00247-3. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13577-019-00247-3)

[3. (Rhead2018Increased) Brooke Rhead, Ina S. Brorson, Tone Berge, Cameron Adams, Hong Quach, Stine Marit Moen, Pål Berg-Hansen, Elisabeth Gulowsen Celius, Dipen P. Sangurdekar, Paola G. Bronson, Rodney A. Lea, Sean Burnard, Vicki E. Maltby, Rodney J. Scott, Jeannette Lechner-Scott, Hanne F. Harbo, Steffan D. Bos, and Lisa F. Barcellos. Increased dna methylation of slfn12 in cd4+ and cd8+ t cells from multiple sclerosis patients. PLOS ONE, 13(10):e0206511, October 2018. URL: http://dx.doi.org/10.1371/journal.pone.0206511, doi:10.1371/journal.pone.0206511. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0206511)

[4. (Basson2018Schlafen) Marc D. Basson, Qinggang Wang, Lakshmi S. Chaturvedi, Shyam More, Emilie E. Vomhof-DeKrey, Sarmad Al-Marsoummi, Kelian Sun, Leslie A. Kuhn, Pavlo Kovalenko, and Matti Kiupel. Schlafen 12 interaction with serpinb12 and deubiquitylases drives human enterocyte differentiation. Cellular Physiology and Biochemistry, 48(3):1274–1290, 2018. URL: http://dx.doi.org/10.1159/000492019, doi:10.1159/000492019. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000492019)

[5. (Singhal2023Schlafen) Sandeep K. Singhal, Sarmad Al-Marsoummi, Emilie E. Vomhof-DeKrey, Bo Lauckner, Trysten Beyer, and Marc D. Basson. Schlafen 12 slows tnbc tumor growth, induces luminal markers, and predicts favorable survival. Cancers, 15(2):402, January 2023. URL: http://dx.doi.org/10.3390/cancers15020402, doi:10.3390/cancers15020402. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers15020402)

6. (Chen2021Complex) Complex Structure of PDE3A–SLFN12 and Structure-based Molecular Glue Design for Apoptosis of Tumor Cells. This article has 0 citations.

[7. (RAAFAT2022SLFN12) AHMED ADHAM RAAFAT ELSAYED, SARMAD AL-MARSOUMMI, EMILIE E. VOMHOF-DEKREY, and MARC D. BASSON. Slfn12 over-expression sensitizes triple negative breast cancer cells to chemotherapy drugs and radiotherapy. Cancer Genomics - Proteomics, 19(3):328–338, 2022. URL: http://dx.doi.org/10.21873/cgp.20323, doi:10.21873/cgp.20323. This article has 9 citations.](https://doi.org/10.21873/cgp.20323)

[8. (Chen2021Structure) Jie Chen, Nan Liu, Yinpin Huang, Yuanxun Wang, Yuxing Sun, Qingcui Wu, Dianrong Li, Shuanhu Gao, Hong-Wei Wang, Niu Huang, Xiangbing Qi, and Xiaodong Wang. Structure of pde3a–slfn12 complex and structure-based design for a potent apoptosis inducer of tumor cells. Nature Communications, October 2021. URL: http://dx.doi.org/10.1038/s41467-021-26546-8, doi:10.1038/s41467-021-26546-8. This article has 24 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-021-26546-8)

[9. (Garvie2021Structure) Colin W. Garvie, Xiaoyun Wu, Malvina Papanastasiou, Sooncheol Lee, James Fuller, Gavin R. Schnitzler, Steven W. Horner, Andrew Baker, Terry Zhang, James P. Mullahoo, Lindsay Westlake, Stephanie H. Hoyt, Marcus Toetzl, Matthew J. Ranaghan, Luc de Waal, Joseph McGaunn, Bethany Kaplan, Federica Piccioni, Xiaoping Yang, Martin Lange, Adrian Tersteegen, Donald Raymond, Timothy A. Lewis, Steven A. Carr, Andrew D. Cherniack, Christopher T. Lemke, Matthew Meyerson, and Heidi Greulich. Structure of pde3a-slfn12 complex reveals requirements for activation of slfn12 rnase. Nature Communications, July 2021. URL: http://dx.doi.org/10.1038/s41467-021-24495-w, doi:10.1038/s41467-021-24495-w. This article has 50 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-021-24495-w)

[10. (AlMarsoummi2021Schlafens:) Sarmad Al-Marsoummi, Emilie E. Vomhof-DeKrey, and Marc D. Basson. Schlafens: emerging proteins in cancer cell biology. Cells, 10(9):2238, August 2021. URL: http://dx.doi.org/10.3390/cells10092238, doi:10.3390/cells10092238. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells10092238)

[11. (AlMarsoummi2020Schlafen) Sarmad Al-Marsoummi, Jonathan Pacella, Kaylee Dockter, Matthew Soderberg, Sandeep K. Singhal, Emilie E. Vomhof-DeKrey, and Marc D. Basson. Schlafen 12 is prognostically favorable and reduces c-myc and proliferation in lung adenocarcinoma but not in lung squamous cell carcinoma. Cancers, 12(10):2738, September 2020. URL: http://dx.doi.org/10.3390/cancers12102738, doi:10.3390/cancers12102738. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers12102738)